Study wrapper · #787
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
Editor's note
This disproportionality analysis of the WHO VigiBase (2010-2024) examined reports of depressed mood and suicidal thoughts with GLP-1 receptor agonists in type 2 diabetes. Researchers reported signals for semaglutide, liraglutide and tirzepatide (adjusted reporting odds ratios of 2.13, 1.52 and 1.07 for depressed mood; 6.76, 2.43 and 3.39 for suicidal thoughts), with no signal for suicide attempts or completed suicide and low absolute reporting frequencies. Crucially, this is a spontaneous-reporting method: it detects reporting patterns, not incidence, and cannot establish causation, and concomitant antidepressant use and comorbid depression were more common in the GLP-1 group, pointing to underlying vulnerability or reporting effects. The authors themselves frame this as supporting monitoring in vulnerable patients rather than a uniform drug effect. Read it as a pharmacovigilance flag, not evidence that these peptides cause mood harm.
Plain-language abstract
Researchers searched the World Health Organization's global database of reported drug side effects to see how often depressed mood and suicidal thoughts were reported with GLP-1 medicines in people with type 2 diabetes. Reports of these symptoms were somewhat more frequent for semaglutide, liraglutide and tirzepatide than for other diabetes drugs, but the overall numbers were low, and there was no increased signal for suicide attempts or deaths. This kind of database can only show reporting patterns; it cannot prove a drug caused the symptoms, and it does not measure how common they truly are. Notably, people in the GLP-1 group were more likely to already have depression or be taking antidepressants, which may explain much of the pattern. The authors suggest keeping an eye on mood, especially early on in vulnerable patients, rather than concluding the drugs are to blame.